Medican Group helps facilities identify medication-related clinical, operational, and regulatory opportunities, organize them for the appropriate team members, and create a clearer path toward follow-up over time.
Medication governance is more than producing reports. It means identifying what matters, explaining why it matters, directing it to the right people, and defining what should happen next.
Explore a Sample Medication Governance ReviewMedication governance is the process of systematically overseeing medication use to promote safe, compliant, and effective medication therapy.
Surface the medication issues that most warrant attention — for individual residents and the facility as a whole.
Provide concise information to leadership, nursing, providers, IDT, and QAPI — in language useful to each audience.
Record what was reviewed, what action was chosen, and what remains unresolved — so nothing quietly drops.
The process begins with available data, identifies priorities, directs appropriate action, and follows progress over time.
Active orders, diagnoses, utilization data, and available clinical information.
Identify high-priority residents and important facility-wide patterns.
State what each finding means and why it matters.
Identify the appropriate next discussion, review, or action.
Carry forward unresolved items and document progress.
These questions help leadership determine whether medication information is actually being translated into useful oversight.
Which residents have the highest medication burden or combined medication-related risk?
Which residents should be discussed with a provider or IDT first?
Are psychotropic indications, behaviors, GDR reviews, and documentation complete?
Which medications may be contributing to falls, sedation, or reduced function?
Are antibiotic indication, duration, and follow-up consistently documented?
Are important recommendations reaching the right people — and being followed?
Each output is concise and tied to a practical responsibility. The figures below are illustrative — representative of the kinds of findings a governance cycle surfaces.
Key facility trends, priority areas, unresolved concerns, and topics for QAPI discussion.
Resident-specific clinical questions and medication decisions that may warrant review.
Psychotropic residents with missing indication, target behavior, or GDR support.
Anti-infective courses with indication, duration, and stop/review-date status.
Recommendations issued, accepted, declined, or open — unresolved items carried month to month.
Screening signals this cycle
Enter a few high-level, de-identified counts and get a simplified read of where a governance review would focus. Everything runs in your browser — no data is uploaded or stored.
Aggregate counts only — no resident names or PHI.
Prefilled with a sample facility — change any number to watch the read update.
17 residents on three or more CNS-active medication categories.
Could medication exposure be contributing to falls, sedation, cognition, bleeding, respiratory risk, or therapy limitations?
812 estimated daily medication administration tasks, at 17.3 orders per resident.
Which schedules, monitoring tasks, PRNs, and legacy orders could be simplified or retired?
41 orders carry cost, duplication, or consolidation signals for review.
Which drug, formulation, OTC, dispensing, and timing decisions add cost without improving outcomes?
26 psychotropic orders lack documented indication or GDR support; 3 antibiotic courses lack a stop date.
Can the chart demonstrate rationale, monitoring, response, duration, and follow-through?
The value of governance shows up in follow-up. When a facility understands when and to whom sedating medications are given, that pattern becomes something the team can actually act on.
It's the difference between a report that gets filed and a finding that changes a resident's night.
Facilities can use these questions to evaluate whether their medication information is reaching the right people, leading to clear action, and being followed over time.